The role of oral antidiabetic agents in improving insulin resistance and body mass index in overweight polycystic ovary patients: a randomized controlled RCT study.
Abstract
Background: Polycystic ovary syndrome is a common hormonal disorder that affects women of reproductive age. It is characterized by irregular menstruation, hyperandrogenism, insulin resistance, obesity, and subfertility, in addition to long-term consequences such as cardiovascular diseases such as atherosclerosis and hyperlipidemia, which justifies the importance of diagnosing and treating this syndrome to improve the quality of life and alleviate the symptoms of androgen excess.
Objective: This article is to determine the optimal treatment to improve insulin resistance and symptoms of androgen hyperactivity in female patients with polycystic ovary syndrome
Methods: The study included female patients with polycystic ovary syndrome in a randomized, unblinded RCT in the Department of Obstetrics and Gynecology at Tishreen University Hospital in Lattakia who met the inclusion criteria. The patients were divided into two groups, the first taking pioglitazone and the second taking metformin. A clinical, laboratory and abdominal ultrasound examination was performed for all participating women in the first visit and after 6 months as well.
Results: Weight and body mass index decreased in both groups. In group B, weight decreased by up to 10% compared to 5% for pioglitazone, with statistically significant differences P = 0.00, and body mass index in group B decreased by 8% compared to 6%, with statistically significant differences P = 0.00. 0.02
Fasting blood sugar concentration decreased in both groups without significant statistical differences
Fasting insulin concentration decreased in both groups, but with a clear advantage for group A, with a statistically significant difference, P = 0.00.
The concentration of insulin resistance decreased in both groups, with a preference for group A, with a statistically significant difference, P = 0.19
Conclusion: Pioglitazone treatment has an advantage over metformin in improving insulin resistance in patients with polycystic ovary syndrome, and in return, metformin is superior in reducing weight and BMl.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.